Presenting the results of two Invesitgational New Drug Trials – IND.221 and IND.226 Wednesday, November 30, 2016 Two Canadian Cancer Trials Group (CCTG) Investigational New Drug (IND) trials – IND.221 and IND.226 – were presented at the 2016 Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR). IND.221, A Dose-Ranging Study of IPH2201 (monalizumab) in Patients with Gynecologic Malignancies, This study was presented by the study co-chair, Dr. Anna Tinker, Medical Oncologist at the British Columbia Cancer Agency, Vancouver, during one of the events Spotlight sessions. The poster presentation showed that data from the dose-ranging part of the phase I/II trial in 18 patients with advanced gynecologic malignancies showed that monalizumab was well tolerated in this patient population, with no dose-limiting toxicities observed. There were no major differences in terms of safety were observed across the different dose levels. The poster presentation: IND221 IND.226, A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients with Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens, aims to confirm the recommended phase II dose (RP2D) of durvalumab ± tremelimumab. Initial results, presented by Dr. Desiree Hao, Medical Oncologist at the Tom Baker Cancer Centre in Calgary, show that durvalumab 15 mg/kg q3w and tremelimumab up to 3 mg/kg q6w has, to date, been safely combined with platinum-doublet chemotherapy. Updated safety data and clinical activity are presented in the poster, which you can view using this link … IND226 These abstracts are available on the EORTC-NCI-AACR Symposium website. Desiree Hao Anna Tinker
